- Home
- IBTA vs GYRE Comparison
IBTA vs GYRE Comparison
Compare IBTA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- GYRE
- Stock Information
- Founded
- IBTA 2011
- GYRE 2002
- Country
- IBTA United States
- GYRE United States
- Employees
- IBTA N/A
- GYRE N/A
- Industry
- IBTA
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- GYRE Health Care
- Exchange
- IBTA Nasdaq
- GYRE Nasdaq
- Market Cap
- IBTA 892.4M
- GYRE 897.1M
- IPO Year
- IBTA 2024
- GYRE N/A
- Fundamental
- Price
- IBTA $30.35
- GYRE $7.30
- Analyst Decision
- IBTA Hold
- GYRE Strong Buy
- Analyst Count
- IBTA 10
- GYRE 1
- Target Price
- IBTA $44.33
- GYRE $18.00
- AVG Volume (30 Days)
- IBTA 380.8K
- GYRE 88.7K
- Earning Date
- IBTA 11-12-2025
- GYRE 11-12-2025
- Dividend Yield
- IBTA N/A
- GYRE N/A
- EPS Growth
- IBTA 2512.20
- GYRE N/A
- EPS
- IBTA 2.84
- GYRE 0.02
- Revenue
- IBTA $367,604,000.00
- GYRE $102,189,000.00
- Revenue This Year
- IBTA N/A
- GYRE $16.80
- Revenue Next Year
- IBTA $1.61
- GYRE $50.29
- P/E Ratio
- IBTA $10.72
- GYRE $429.99
- Revenue Growth
- IBTA 3.49
- GYRE N/A
- 52 Week Low
- IBTA $22.50
- GYRE $6.11
- 52 Week High
- IBTA $79.80
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- GYRE 43.73
- Support Level
- IBTA N/A
- GYRE $7.20
- Resistance Level
- IBTA N/A
- GYRE $7.72
- Average True Range (ATR)
- IBTA 0.00
- GYRE 0.27
- MACD
- IBTA 0.00
- GYRE -0.02
- Stochastic Oscillator
- IBTA 0.00
- GYRE 21.86
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.